SCYX - Scynexis Inc logo

SCYX

Scynexis Inc

Net โ€”top 1%Rev โ€”top 1%10Y
Hold

Scynexis Inc. is a biotechnology company focused on developing treatments for difficult-to-treat fungal infections. Its primary product, BREXAFEMME, targets vulvovaginal candidiasis, while SCY-247 is in clinical trials for invasive fungal infections.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$28today

Score Overview

1 Year
Scoreโ€”
Net Growthโ€”
Net Trendโ€”
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trendโ€”
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growthโ€”
Net Trend50%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend50%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growthโ€”
Net Trend56%
Net Income Consistency
Rev Growthโ€”
Rev Trend44%
Revenue Consistency
All Time
Scoreโ€”
Net Growthโ€”
Net Trend55%
Net Income Consistency
Rev Growthโ€”
Rev Trend36%
Revenue Consistency

See the full market ranking โ†’

Scynexis Inc fundamental performance

Across Scynexis Inc's full reported history, from 2014 to 2025, revenue grew from $ 1M to $ 20M and net income went from -$ 4M to -$ 8M. Revenue increased in 36% of the years measured; net income in 55%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 4.81โ€”
1 Year2025-08-12
$ 6.88-30.08%
5 Years2021-08-12
$ 50.96-90.56%
10 Years2016-08-12
$ 172.80-97.22%
All Time2014-05-02
$ 720.00-99.33%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 54M
2025$ 20M-$ 8M$ 21M
2024$ 3M-$ 21M$ 59M
2023$ 140M$ 67M$ 74M
2022$ 5M-$ 62M$ 73M
2021$ 13M-$ 32M$ 104M
2020$ 12M-$ 55M$ 93M
2019$ 121K-$ 53M$ 48M
2018$ 257K-$ 12M$ 44M
2017$ 257K-$ 25M$ 43M
2016$ 257K-$ 29M$ 58M
2015$ 257K-$ 32M$ 46M
IPO2014$ 1M-$ 4M$ 32M

Explore beyond SCYX

You're looking at Scynexis Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies